Capstone Partners has released its latest Bio/Pharma Outsourced Services (BPOS) industry report highlighting new opportunities for contract development manufacturing organizations (CDMOs). As noted in the report, the increasing volume of gene therapy drugs under development will require greater manufacturing capacity and, in turn, greater utilization of CDMO capacity. CDMOs may be able to increase penetration of their outsourced manufacturing services by providing services at the commercial stage in addition to the earlier stages of preclinical development and clinical trials. The full report is available for download below.
Insights for Middle Market Leaders
Receive email updates with our proprietary data, reports, and insights as they’re published for the industries that matter to you most.